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Alzheimer’s disease (AD), the most frequent cause of
dementia, is escalating as a global epidemic, and so
far, there is neither cure nor treatment to alter its
progression. The most important feature of the
disease is neuronal death and loss of cognitive
functions, causedprobably fromseveral pathological
processes in the brain. The main neuropathological
features of AD are widely described as amyloid beta
(Ab) plaques and neurofibrillary tangles of the aggre-
gated protein tau, which contribute to the disease.
Nevertheless, AD brains suffer from a variety of
alterations in function, such as energy metabolism,
inflammation and synaptic activity. The latest dec-
ades have seen an explosion of genes and molecules
that can be employed as targets aiming to improve
brain physiology, which can result in preventive
strategies forAD.Moreover, therapeuticsusing these
targets canhelpADbrains to sustain functionduring
the development of AD pathology. Here, we review
broadly recent information for potential targets that
canmodify AD through diverse pharmacological and
nonpharmacological approaches including gene
therapy. We propose that AD could be tackled not
only using combination therapies including Ab and
tau, but also considering insulin and cholesterol
metabolism, vascular function, synaptic plasticity,
epigenetics, neurovascular junctionandblood–brain
barrier targets that have been studied recently. We
alsomake a case for the role of gut microbiota in AD.
Our hope is to promote the continuing research of
diverse targets affecting AD and promote diverse
targeting as a near-future strategy.
Keywords: AD gene therapy, AD molecular targets,
AD therapeutics, alzheimer´s disease, amyloid beta
therapies, Tau therapies.
Introduction
Alzheimer’s disease is a steadily growing global
epidemic. Estimates suggest more than 47 million
people worldwide were affected in 2015 and a
staggering 131 million is predicted 30 years from
now [1–4]. AD is a neurodegenerative disorder
characterized mainly by the loss of memory func-
tions and accompanied by other symptoms in a
wide range of classes from mood, verbalization to
motor problems. The most striking outcome from
this type of dementia is the incremental disability
for performing everyday life routines and increas-
ing dependence from others for care. Aging is the
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main risk factor for developing AD [5, 6], and the
risk of developing AD dementia becomes even
higher as life expectancy increases and the world
population becomes older [5, 7]. Other reviews
have dealt extensively with the economic burden
this disease represents for countries [1, 4], esti-
mating it at 0.65% of the world gross domestic
product, a cipher rarely seen for a single disease
[8]. Moreover, it is likely that the economic burden
for AD is largely underestimated since it is difficult
to account for the expenditure from family mem-
bers paying for nursing or stop working to take care
of their relatives [7, 9, 10]. Thus, solving the AD
puzzle should be hand in hand with increasing the
lifespan of humans, in order to reach for healthy
aging, one of the main goals for the World Health
Organization (WHO) and for many states worldwide
[11, 12].
Currently, AD has no treatment available to modify
its progression. Pioneering efforts from scientists
and clinicians led to discovery and development of
cholinesterase inhibitors for AD, capable of
improving symptoms such as mood swings or
dyskinesia, but these treatments do not halt AD
progression nor improve memory performance in
patients, as revised by Schneider et al. [13] and by
Mangialasche et al. [14]. Antibody therapies have
been developed from the main pathological hall-
marks of AD, Amyloid beta (Ab) and Tau proteins,
to normalize their levels in the brain. These ther-
apies are based on the amyloid cascade hypothe-
sis, proposing that Ab and Tau accumulation in the
brain mediates synapse loss and neuronal death,
leading to diminished memory function [15]. Nev-
ertheless, many clinical trials aimed at reducing
amyloid levels have not reached significant
improvement in memory performance, or caused
secondary, often-adverse effects and have dropped
out [16]. Moreover, some failed clinical trials also
led to the scientific community to explore addi-
tional hypotheses for AD pathogenesis [17–21].
Therefore, it hasbecomemore important to generate
novel strategies and targets that will effectively alter
in any form of the progression and the underlying
causes ofmemory loss in AD. Novel evidence behind
alternativemechanisms of the disease and improve-
ments in technology from imaging to gene editing
has opened new lines of research that could help to
explain the origin and progression of AD [22–25]. In
addition, the field is moving increasingly towards
earlier and more accurate diagnostic of the pathol-
ogy, where technology can help us to better classify
and even redefine AD [26]. This review summarizes
pioneering efforts in mechanisms of disease and
novel drug targets for Alzheimer0s disease research.
We would like to emphasize the importance of
multidisciplinary research in finding new treatment
avenues in what it is a complex disease with many
challenges.
Different treatment approaches based on pathogenesis
Synaptic plasticity and AD
Neuroplasticity is a complex response of neurons
to endogenous and exogenous stimuli; it is a
continuous process that embraces learning and
memory processes. Neuroplasticity comprises mor-
phological and functional interchanges, including
differences in synaptogenesis, remodeling of
the synaptic, axon and dendritic structures, and
generation of new neurons (neurogenesis). All
brain tissues are associated to neuroplasticity but
hippocampus, neocortical areas and cholinergic
basal forebrain neurons, which are involved in the
regulation of higher brain functions, such as
learning, memory and cognition, maintain an ele-
vated degree of plasticity during all life stages.
The adult central nervous system (CNS) has a
limited, although effective, ability to restore synap-
tic circuitry and its impact on cognition remains
controversial. Furthermore, mechanisms that reg-
ulate neuroplasticity seem to be involved in neu-
rodegenerative diseases. It is of interest to note that
brain regions with elevated neuronal plasticity
develop more slowly during infancy and are the
most vulnerable in the aging and in AD. A dispro-
portion between synapse formation and elimina-
tion could be responsible for defective plasticity
during ageing and disease. If defective mechanisms
controlling developmental plasticity are reactivated
in later life, they could contribute to inefficient
plasticity processes [27].
Memory deficits in AD could be related to early
events that come before neurodegeneration, such
as synaptic loss and dysfunction. Synapse degen-
eration is believed to begin with dendritic spines
and with decreased quantity of molecules that
regulate spine signaling [28].
Insoluble Ab fibrils are taken into consideration as
the main responsible for spine pathology. On the
other hand, in both transgenic mouse models of AD
and human AD brain, synapse defects and memory
loss correlate weakly with the presence of Ab
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plaques and could take place before the formation
of plaques. Indeed, small neurotoxins comprised of
soluble Ab oligomers (Ab-derived diffusible ligands,
ADDLs), present in the brain and cerebrospinal
fluid of AD patients, are ligands able to compro-
mise synaptic plasticity, even at nanomolar con-
centrations, by binding to dendritic spines or by
the interference of transcription factor activation,
mediated by N-methyl-D-aspartic acid (NMDA)
receptors [29–31] (See Fig. 1).
Bidirectional trafficking of proteins at postsynaptic
level is a mechanism involved in synaptic plastic-
ity. For example, synaptic activity and activation of
AMPA/NMDA receptors control AMPA receptor
sorting. Moreover, endocytosis and exocytosis are
involved in long-term potentiation (LTP) and long-
term depression (LTD) of hippocampal synapses.
Induction of LTP and LTD are prevented by block-
ing exocytosis and endocytosis, respectively. Recy-
cling endosomes located at the spine level regulates
spine growth, suggesting that stimulation of endo-
cytosis and dendritic spine could promote plastic-
ity [32].
Kinases play a critical role in synapse formation and
plasticity. For example, the mitogen-activated pro-
tein kinase (MAPK)/extracellular signal-regulated
kinase (Erk) pathway mediates the synaptogenic
action of neurotrophic factors. This intracellular
pathway could contribute to long-term synaptic
plasticity by coordinating the activity of transcrip-
tion factors and their subsequent nuclear translo-
cation. MAPKs are located and active in synaptic
terminals, suggesting a role in subcellular compart-
ments during short- and long-term plasticity by
phosphorylation of synaptic targets. Cyclin-depen-
dent kinase-5 showsmany roles in spine formation,
expression of proteins in postsynaptic neurons, as
well as in the phosphorylation of numerous mole-
cules important for synaptic plasticity [33].
The immunoglobulin and cadherin super families
of cell adhesion molecules control cell migration,
growth of axons and synapse formation. The neural
cell adhesion molecule (NCAM), expressed in neu-
ron and glia cell surface plasma membrane, regu-
lates the consolidation of learning and memory
processes. Enreptin, a peptide agonist of NCAM,
enhances long-term memory and reduces neuronal
death. Furthermore, the cell adhesion molecule N-
cadherin regulates spine stability. Synaptic cell
adhesion molecules interact with Ab and also
control its production by regulating the activity of
enzymes involved in Ab formation. Ab-dependent
reduction of synaptic adhesion alters function and
integrity of synapses, indicating an important role
of synaptic adhesion in the maintenance of neu-
ronal integrity [34].
The family of neurotrophins regulates synapse
formation and synaptic plasticity. Nerve growth
factor (NGF), a member of the neurotrophin family,
promotes the synaptic function of cholinergic basal
forebrain neurons, which contribute to memory
process. Considering the regenerative effect of NGF
on cholinergic neurons, its targeted delivery has
emerged as a potential therapy for AD. Recently, a
small clinical trial inserting encapsulated NGF-
producing cells in AD patients has shown safety
and tolerability increasing cholinergic markers in
CSF [35]. Long-term exposure of hippocampal
neurons to brain-derived neurotrophic factor
(BDNF, another neurotrophin with structural sim-
ilarity to NGF) modulates synaptic transmission
and plasticity and effects structural changes of
dendrites, spines and presynaptic terminals. More-
over, BDNF exposure has effects on the synaptic
proteome, by affecting protein synthesis or degra-
dation [36].
Glial cells are involved in nervous system stability
and synaptic plasticity. Glial processes ensheath
synapses, support their development and func-
tions and secrete proteins (e.g. thrombospondins)
that promote CNS synaptogenesis. Complement
C1q and C3, upregulated in neurons exposed to
astrocytes, participate in synapse elimination.
Patients with frontotemporal dementia have low
levels of progranulin (a protein antagonist of
tumor necrosis factor-alpha (TNF-a)), which
results in defects of lysosomal functions and
excessive activation of complement, causing
synaptic pruning by microglia and behavioural
defects rescued by blocking complement activa-
tion [37].
17b-estradiol (E2) supports dendrite growth, spine
and synapse formation in both developing and
adult CNS. In the hippocampus, E2 modulates
synaptic plasticity slowly (genomically via classical
nuclear receptors) and rapidly (nongenomically via
extranuclear receptors) [38]. Nanomolar concen-
trations of E2 cause changes in hippocampal spine
morphology. Activation of neuronal glutamate
receptors, by glutamate released from astrocytes
in response to PGE2, modulates dendritic spine
density [39].
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The role of inflammation in AD is well recognized.
Elevated levels of TNF-a, a pro-inflammatory
cytokine responsible for the neuroinflammatory
response, have been reported in brain and plasma
of AD patients. TNF-a modifies synaptic transmis-
sion and strength. Synaptic scaling, which is a
homeostatic mechanism that takes part in the
synaptic dysfunction in AD may be the mecha-
nism involved in these events. As TNF-a modu-
lates synaptic scaling, alteration of synapsis
mediated by elevated levels of TNF-a could con-
tribute to cognitive and behavioural impairments
in AD [40].
In summary, in the mammalian CNS, dendritic
spines are essential for synaptic function and
plasticity. AD and other CNS disorders have a
strong relation with aberrant dendritic spines.
Synaptic plasticity and spine alteration can be
influenced by many factors, including Ab, impaired
glucose and lipid metabolism, steroids, kinase
pathways, cell adhesion molecules, neurotrophic
factors, glial cells and inflammation. A better
knowledge of cellular and molecular molecules
able to control the age and/or cognitive abilities
may lead to effective treatments for age-associated
Fig. 1 Dendritic spine and AD: mechanisms causing spine degeneration. An impaired synaptic plasticity is an early event
in Alzheimer disease (AD). Synaptic plasticity is accompanied by morphological adaptations of dendritic spines, such as
changes in the number and shape of spines (structural plasticity). A fundamental mechanism for modification of synaptic
strength is insertion (activation) or removal (inactivation) of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
receptors (AMPARs) at the postsynaptic membrane. Such adaptation occurs within minutes, yet may also extend over longer
times. Ab1–42 over-activates NMDAR/calmodulin (CaM)/calcineurin/glycogen synthase kinase-3b (GSK-3b). Calcineurin, a
calcium-sensitive phosphatase, regulates synaptic plasticity and is required for AMPARs internalization and long-term
depression. Ab oligomer-induced AMPARs endocytosis and spine loss are prevented by calcineurin inhibition. Therefore,
inhibition of calcineurin could be a therapeutic strategy for combating early-stage AD impairment.
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memory impairment and for other, more severe
cognitive impairments, in particular AD.
Epigenetics and AD
Epigenetics involves heritable changes in gene
function not caused by mutations in DNA sequence
[41]. Such changes may relate to chromosomal
ones that affect gene activity and expression, as
well as heritable phenotypic changes that do not
derive from genome modification. These effects on
cellular and physiological phenotypic traits could
be driven by external or environmental factors, or
be part of a normal developmental programme.
Numerous CNS physiological functions (neural
stem cell fate determination, neural plasticity,
and learning and memory) have significant epige-
netic components. This is the case also for neu-
rodegenerative diseases. For example, in Alzheimer
disease (AD), both genetic and non genetic factors
contribute to disease etiopathology. Whilst over
250 gene mutations have been related to familial
AD, <5% of AD cases are gene-related.
At least three systems including DNA methylation,
histone modification and noncoding RNA (ncRNA)-
associated gene silencing can initiate and sustain
epigenetic change. More than likely nongenetic
factors, probably triggered by environmental fac-
tors, are causative factors of late-onset AD. Many
CNS pathologies, including AD are associated with
dysregulation of DNA methylation, histone modifi-
cations (deacetylation, phosphorylation, ubiquity-
lation and SUMOylation) and ncRNAs [42]. Histone
phosphorylation, in particular, appears to be part
of a complex interplay between other epigenetic
markers, such as histone acetylation and methy-
lation, and DNA methylation.
Indeed, histone phosphorylation increases pro-in-
flammatory gene activation [43]. A number of pro-
teins involved in AD pathology (amyloid precursor
protein (APP), Tau, b-site amyloid precursor protein
cleaving enzyme 1 (BACE1), glycogen synthase
kinase-3b and c-Jun N- terminal kinase) are SUMO
(small ubiquitin-like modifier) targets [44]. Further-
more, AD patients have altered levels of SUMOyla-
tion and SUMO-related protein expression [45].
Amongst the classes of ncRNA, microRNAs (miR-
NAs) are highly expressed in CNS neurons, where
they play a major role in neuron differentiation,
synaptogenesis and plasticity. MicroRNAs impact
higher cognitive functions, as their functional
impairment is involved in the aetiology of neuro-
logical diseases, including AD [46]. A growing body
of evidence points to alterations in the miRNA
network as active contributors to AD disease
processes [47]. Alterations in the miRNA network
contribute to AD disease pathogenesis by (i) reg-
ulating expression of APP and other enzymes
involved in Ab processing, in particular BACE1;
(ii) Neurofibrillary tangles in AD brain are com-
posed mainly of hyperphosphorylated Tau, whose
state of phosphorylation represents a fine balance
between kinases and phosphatases, processes
that may be regulated by miRNAs; (iii) regulation
of lipid metabolism [48]; and (iv) neuroinflamma-
tion [49].
Understanding epigenetic dysregulation in AD
could contribute to our view of the origin and
progression of AD and, possibly, the development
of efficacious therapeutics. However, one caveat
with epigenetic studies is the issue of causality.
Yet, given the failure of AD clinical trials to date,
focus is now shifting to diagnose AD at as early a
stage as possible, even before onset of cognitive
decline. Despite the inherent difficulties, timely
disease detection offers a multitude of benefits, not
the least of which are opportunities for early
intervention and better management of symptoms.
miRNAs have emerged as potential candidates for
reliable biomarkers of early-stage AD, being pre-
sent in biofluids and displaying high stability in
terms of storage/handling. Moreover, ncRNAs,
miRNAs—and especially long ncRNAs—as thera-
peutic targets are only beginning to be considered.
Even so, these transcripts represent potential
targets for two reasons: (i) long ncRNA expression
seems to be rather cell- and tissue-specific; (ii) the
sequence-specific function of long ncRNA can be
advantageous in designing specific therapies.
Blood–brain barrier targets
Blood–brain barrier (BBB) is a multicellular vas-
cular structure that separates the central nervous
system (CNS) from the peripheral blood circulation.
The core anatomical element of the BBB is the
cerebral blood vessel formed by endothelial cells
(ECs). Mural cells represented by pericytes and
astrocytes sit on the abluminal surface of the
microvascular endothelial tube. Astrocytes interact
with neurons and microglia. Both pericytes and
astrocytes interact with ECs and maintain the
sealing of interendothelial tight and adherent
junctions, loss of leucocyte adhesion molecules
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and inhibition of transcytosis [50–53]. The vascu-
lar tube is surrounded by two basement mem-
branes, the endothelial vascular basement
membrane corresponded to an extracellular matrix
secreted by the ECs and pericytes, and the
parenchymal basement membrane primarily
secreted by astrocytic processes that extend
towards the vasculature. The molecular compo-
nents of these basement membranes also con-
tribute to the complexity of the barrier [54].
Besides, these complex cellular interactions which
correspond to the neurovascular unit instead of
BBB, endothelial cells express different types of
transporters and receptors amongst which some
are involved in the efflux and influx of the amyloid
peptide [55, 56]. Beyond barrier function, influx
and efflux are actively regulated at the blood–brain
interface. Moreover, recent research has uncovered
different transcription factors involved in pheno-
type change (zonation) along the vessels of the BBB
[57]. The BBB maintains an environment that
allows neurons to function properly by tightly
controlling the passage of molecules and ions,
instantaneously delivering nutrients and oxygen
according to current neuronal needs, and by pro-
tecting the brain from toxins and pathogens. We
now know that the cellular and molecular com-
plexity of the BBB explains that the dysfunction of
a cellular or molecular actor can disrupt its
dynamics, although the precise process is unclear
[58].
Blood–brain barrier in AD
Several impairments of the neurovascular unit
have been described in Alzheimer’s disease (AD),
but the time-point at which they occur during
disease pathogenesis remains unclear because
they are too often seen in post-mortem brains.
However, for the past 3 years, medical imaging has
demonstrated the early BBB disruption in the
hippocampus even before the onset of hippocampal
atrophy [59]. In addition, many studies indicated
cerebral microbleeds (micro haemorrhages) in AD
[60, 61]. Compared with controls, BBB P-glycopro-
tein activity was significantly lower in the pari-
etotemporal, frontal and posterior cingulate
cortices and hippocampus of mild AD subjects by
PET-scan [62]. Besides, many morphological and
functional changes in brain vasculature in AD were
observed: thinning of microvessels, referred to as
atrophic or string vessels; twisted or tortuous
vessels and fragmented vessels [63]; thickening
and vacuolization of the vascular basement
membrane with increase of collagen IV [64]; leak-
age and accumulation of circulating plasma pro-
teins with direct neurotoxic properties and
erythrocyte-derived haemoglobin in brain [56].
Additional changes include also pericyte loss [65],
astromicrogliosis, many molecular changes
directly impacting the clearance of the amyloid
peptide (decrease of GLUT-1, LRP-1, P-gp and
increase RAGE) [60], hypoperfusion and perme-
ability failure [66].
Chemokines as critical targets for diagnosis or
therapeutic strategies
Amongst the peripheral molecular actors, we can
target chemokines. Indeed, many articles have
shown the involvement of chemokines in the
pathophysiology of AD [67]. Of those that are
deleterious, the pro-inflammatory chemokines
CXCL10/CXCR3, CCL3, CCL4, CXCL8/CXCR8
and CX3CL1/CX3CR1 increase in AD, lead to
inhibition of Ab clearance, increased adhesion of
PBMCs [68–73]. On the contrary, CCL5 is known
as neuroprotective [74, 75]. Besides the too high or
too low levels of some chemokines including CCL2
are unfavourable in AD because the physiological
activation of the CCL2/CCR2 signalling pathway is
crucial to limit the progression of the disease in AD
experimental models [76–78].
In the light of these elements of the literature, we
studied the impact of PBMCs issued from AD
patients on the chemokines’ signature at the level
of a healthy BBB, given that the current data on
chemokine levels are derived from isolated biolog-
ical samples (Plasma, serum, brain and cell cul-
ture) whilst BBB displays a great cellular and
molecular complexity, finely orchestrated to pre-
serve the brain.
In a human BBB model comprising two cell lines,
an endothelial cell line (hCMEC/D3) and U87 cell
line (human glioblastoma), PBMCs from patients
(control, mild and moderate AD patients) were
added in the luminal medium. It should be noted
that all analyses were also performed on isolated
cultures of each cell type and on a BBB model
without PBMCs. A previous work on a group of
patients with AD at a moderate stage has already
been published, and we also verified in this study
with the 3 groups of patients the interest to go to
an integrated model to take into account the
cellular and molecular interactions in the neu-
rovascular unit [79]. Results showed that PBMCs
from moderate AD patients decreased CCL2 and
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CCL5 levels in luminal and abluminal compart-
ments (2-3-fold) and CXCL10 only in the ablumi-
nal compartment (3-4-fold) compared to PBMCs
from mild AD patients. Levels of CCL2 and CCL5
also significantly decreased on PBMCs of moderate
AD patients compared to PBMCs from mild AD
patients. The CX3CL1 expression increased in
luminal and abluminal compartments with
PBMCs from mild AD patients compared to con-
trols [80].
In a murine BBB model (French patent in August
2017 and PCT extension in August 2018), the
impact of mouse PBMCs from transgenic mice
(APPswePS1dE9) or their control littermates in
the signature of chemokines in BBB prepared from
mouse brains was studied at 3, 6 and 12 months.
In this model, a healthy abluminal compartment is
used, and PBMCs and luminal compartments
came from AD or wild-type mice. Compared to
results obtained in human BBB model, we also
showed a decrease in CCL2 expression (about 6-
fold) in the abluminal medium by PBMCs issued
from AD mice at 12 months compared to WT mice.
Furthermore, results showed an increase in
CX3CL1 in the abluminal compartment (2.3-fold)
and a decrease (4-5 fold) in cells used in luminal
compartment in 12-month-old mice compared to 3-
month-old mice [80].
In both BBB models, the PBMCs come from
patients or mice with advanced disease (moderate
and 12 months) and the abluminal compartment is
healthy. Even if the luminal compartment is AD in
the mouse model, we observed:
• a significant decrease in CCL2 in abluminal
compartment with AD PBMCS (moderate stage
or 12 months)
• an early increase in CX3CL1 (mild versus con-
trols) in luminal and abluminal media and also
an increase in abluminal compartment with
mouse AD PBMCs (12 months versus 3 months).
It is known that the variations of these two
chemokines are deleterious in AD, and it has been
demonstrated that they are induced by PBMCs
from AD patients or mice with advanced AD. Thus,
the results join other publications highlighting an
origin of peripheral blood in AD. The modulation of
the blood–brain interface by targeting CCL2 and
CX3CL1 could be a new therapeutic pathway.
Neurovascular junction damage and therapeutic targets: insights
from preclinical research on vascular dementia and microbleeds
Vascular dementia and its most prominent sub-
type, subcortical atherosclerotic encephalopathy
(M. Binswanger), represent the second most fre-
quent and important form of dementia in the
elderly after Alzheimer’s disease. It represents
about 15% of all dementia cases, whilst another
15% of cases are mixed forms occurring together
with Alzheimer’s disease. Vascular dementia has
therefore rapidly gained attention as a growing
medical and socioeconomic burden. Vascular
dementia and, in particular, M. Binswanger are
characterized by progressive white matter lesions
that are strongly related to cognitive decline and
believed to be an important pathophysiological
hallmark of almost half of all dementias in the
elderly (and even beyond ‘pure’ forms of vascular
dementia [81]. Symptoms of vascular dementia are
also observed in cases of disseminated cerebral
microbleeds.
Despite its significant impact, relatively little is
known about central pathogenic mechanisms, and
no casual treatments are available so far. It is
known, however, that hypertension plays an
important role in vascular dementia and rigorously
controlling blood pressure may slow down its
progress. In turn, increased systolic BP progres-
sively disrupts white matter integrity already in
young adults and increases the risk for late-life
dementia [82].
In human vascular dementia patients, microbleeds
and lacunar infarcts typically occur in the basal
ganglia whilst white matter hyperintensities pref-
erentially develop in the centrum semiovale.
Anatomical factors might explain these differing
predilection sites: arterioles entering the deep
white matter from the superficial cortex are coated
by a single leptomeningeal layer rendering them
more susceptible to hypertension-related vascular
damage [83, 84]. Microbleeds preferably appear in
the basal ganglia.
In this section, current findings will be outlined
from preclinical research that may indicate such
novel therapeutic targets for vascular dementia,
which, at least in part, may also be relevant for
Alzheimer’s disease. Potential therapeutic
approaches will also briefly be presented.
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Preclinical research in vascular dementia: state of
the art
Preclinical research in vascular dementia relies on
a number of animal models, most of which sepa-
rately mimic a selected aspect of human disease,
predominantly lacunar infarcts, white matter dam-
age and vessel dysfunction. An important animal
model is stroke-prone spontaneously hypertensive
rats (SHR-SP). They feature most of the cardinal
histopathological signs of cerebral small vessel
disease (cSVD) [85] likely as a consequence of
chronically increased arterial blood pressure that
causes vascular dysfunction [86]. However, the
SHR-SP model is biased towards the bleeding facet
of cSVD [87] which might be due to genetically fixed
alterations of the endothelial tight junctions [88]
and a massively increased blood pressure by far
exceeding that observed in human patients. Recent
research on SHR, which present high, but not
extremely increased systolic blood pressure,
revealed very similar behavioural and histological
findings as seen in human vascular dementia
patients [89] (Fig. 2). Moreover, a number of dis-
ease-driving alterations such as focal BBB
breakdown, macro- and microglial activation, and
immune alterations may also provide promising
targets for early-stage AD (Fig. 2).
Behavioural changes in SHR, white matter and BBB
breakdown
Middle-aged SHR showed a reduced discrimination
capability between known and unknown objects,
indicating a decline of the nonspatial working
memory, primarily related to frontal-subcortical
circuits [90]. Spatial memory is initially not
affected. However, spatial memory deficits being
typical in human vascular dementia patients [91]
may develop over time since time-dependent loss of
cornu ammonis 1 pyramidal neurons occurs in
SHR [92].
Macro- and microglial activation
A sustained macro- and microglial activation in
deep cortical regions can be observed in SHR.
Although the number of Iba1-positive microglia in
DCR is comparable results between SHR and
normotensive Wistar Kyoto rats (WKY), single-cell
morphological analysis increased cellular volumes
Fig. 2 Spontaneously
hypertensive rats as a model of
vascular dementia.
Spontaneously hypertensive
rats develop cognitive deficits
in their middle age that
continue to aggravate with age.
The animals also show an
increasing loss of brain tissue
with age, particular in in-deep
cortical regions, subcortical
areas and the corpus callosum.
The primary cause of this
cognitive decline could be
chronic hypertension and the
animals exhibit a number of
pathophysiological hallmarks
of vascular dementia such as
blood–brain barrier damage,
impaired microcirculation, glial
response and chronic
inflammation. Scheme drawing
based on study of Kaiser et al.
[89]
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being indicative of microglial hypertrophy. Micro-
glial activation is further indicated by increased
CD11b expression [89].
Immunological mechanisms potentially contributing
to vascular dementia
There is increasing evidence that the immune
system significantly contributes to the develop-
ment and progression of vascular dementia. For
instance, serum levels of soluble adhesion mole-
cules were increased in patients with white matter
lesions [93] and c-reactive protein (CRP) levels
correlate with the existence and progression of
white matter damage [91]. The association of
inflammation and vascular dementia is not sur-
prising since chronic inflammation also plays an
important role in the pathophysiology of its pri-
mary risk factor hypertension [94, 95]. However,
whether such inflammatory processes initiate vas-
cular and tissue damage, promote its propagation
or simply constitute a response to ongoing reorga-
nization remains unclear. Similar relationships
have been described for Alzheimer’s disease.
Distribution of blood-borne leucocytes differs
between SHR and WKY strains. In WKY, T cells
were mostly localized within the meninges and the
choroid plexus (CP), whilst the majority of T cells
populated microvessels within the SHR brain
parenchyma. The different T cell distribution
patterns may be explained, for instance, by an
upregulation of VCAM-1 in brain endothelial cells,
which occurs as a consequence of an activated
renin-angiotensin system during arterial hyper-
tension in hypertensive rats [96] and vascular
dementia patients [97]. The increased presence of
T cells adhering to the luminal side of cerebral
microvessels might indicate slowed vascular tran-
sit time of leucocytes due to pseudopod formation
[98] or may be part of a systemic adaptive immune
response against vascular neoantigens. Impor-
tantly, T cells directly promote endothelial dys-
function.
An interesting finding was the considerable
decrease of T cells in the meningeal space and the
choroid plexus of SHR. Meningeal T cells have a
significant impact on learning behaviour, memory
function and mood stabilization [99]. Moreover,
higher amounts of natural killer (NK) cells were
present in the SHR brain.
Besides their direct participation in endothelial
dysfunction (as an indicator of BBB disintegration),
T and NK cells may play an important role in
cerebral arteriogenesis [100] owing to perfusion
deficits and shear stress. Increased angiogenesis
helps to restore the neurovascular junction in
areas where blood vessels become rare due to
continuous vascular damage. This may indicate
repair processes, along with an increase of DCX-
positive neural progenitors in the SHR subventric-
ular zone. Neurogenesis might indeed be initiated
by white matter injury in vascular dementia [101].
Preclinical research on post haemorrhage neuronal
damage: novel insights
Recent clinical evidence suggests that the occur-
rence of microbleeds leads to a greater cognitive
decline in vascular dementia and AD [102–104]. In
the Rotterdam Study, higher levels of plasma Ab
were associated with increasing lacunar and
microbleed counts [105]. However, microbleeds
are often functionally asymptomatic in patients
[106, 107] and are therefore difficult to detect
clinically, except using modern imaging technol-
ogy.
Furthermore, cognitive decline is particularly wors-
ened when microbleeds occur in deep brain regions
or simultaneously in lobar and deep structures
[103]. Blood breakdown products may lead to
axonal and white matter injury of fibres trespass-
ing the lesion site resulting in delayed, distal cell
death. There is evidence from larger brain haem-
orrhages in the basal ganglia that axonal degener-
ation occurs in the internal capsule due to its close
proximity. For example, Wallerian degeneration is
common in intracerebral haemorrhage (ICH)
patients and occurs particularly in the corti-
cospinal tract in deep ICH [108].
The underlying molecular mechanisms of how
microbleeds promote cognitive decline and axonal
degeneration/white matter damage remain incom-
pletely understood. Blood breakdown products
released from the bleed can cause neuronal cell
death engaging nonapoptotic forms of regulated
cell death [109, 110]. In addition, it is known that
degeneration of axons, in general, occurs actively,
but autonomously from neuronal cell body death,
and via different molecular mechanisms [111].
Whilst neuronal cell bodies may die via the canon-
ical caspase-3-dependent apoptotic pathway,
blockade of this pathway does not prevent axonal
degeneration [112]. Axon degeneration depends on
the proapoptotic family member bax and requires
caspase-6 [113].
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Gut microbiota and AD
In AD subjects, higher levels of pro-inflammatory
cytokines have been found, together with reactive
microglial cells co-localizing with amyloid plaques.
It has been proposed that high levels of inflamma-
tion are a consequence of Ab signalling [114, 115].
However, recently this hypothesis has been revised
since the induction of the pro-inflammatory state
can promote the amyloid cascade. It is in this
context that we look at the role of the microbiota.
The gut microbiota has been named our other
brain for the functional connections between the
two. The microbiota weighs as much as the brain
itself (up to 1.5 kg [116]) and is made of bacteria,
viruses and fungi. The number of bacteria in the
gut exceeds the number of somatic cells by 10-fold
and the number of microbial genes (the micro-
biome) exceeds the number of human genes by
100-fold [116, 117].
The human gut has bacteria with pro-inflamma-
tory and others with anti-inflammatory properties,
in dynamic homeostatic balance. Different stres-
sors can lead to dysbiosis, that is an imbalance
between pro- and anti-inflammatory bacteria that
has been invoked to explain observations in
patients with rheumatoid arthritis, atherosclerosis,
obesity and other diseases (Fig. 3) [118].
The Gut microbiota and the immune system in AD
Differences in the gut microbiota composition have
been described, suggesting a specific microbial
signature typical of AD [120]. The question arises
of the causality behind these intestinal changes
and brain pathology. The immune system seems to
play a crucial role in the gut–brain communication.
Higher levels of peripheral and central pro-inflam-
matory cytokines have been found in AD patients
as compared to controls; reactive microglial cells
co-localize with amyloid plaques, indicating that
the pathology is accompanied by peripheral and
neuroinflammation [114, 115]. Importantly, gut
microbiota communicates with the immune sys-
tem, for example by inducing T regulatory cells to
turn off inflammatory processes [121], but alter-
ations in its composition have been seen to be
related to inflammatory pathologies. A dysbiotic
flora, indeed, produces metabolites or release
molecules, such as lipopolysaccharides, that can
induce a peripheral inflammatory response, which,
in turn, could reach the brain. In case of gut
microbial dysregulation, both the intestinal barrier
and the blood–brain barriers become more leaky,
leading to an augmented passage of these mole-
cules, from the gut into the circulation [122, 123].
In AD, inflammation has always been considered
one of the downstream phenomena of amyloid
deposition. However, recent findings showed that
immune system activation and a pro-inflammatory
state could promote amyloid deposition [114]. In
this regard, preclinical studies indicated that Ab
exerts antimicrobial properties: temporal lobe
homogenates from AD patients inhibit Candida
albicans growth, in a dose-dependent manner, as
compared to non-AD temporal lobe homogenates
or to cerebellum homogenates from AD patients
[124]. In a mouse and a nematode model of AD the
presence of Ab protected from Salmonella or C.al-
bicans infection by creating a net that entrapped
microbes and prevented their adhesion to the host
[125]. As the immune system regularly produces
amyloid nets to entrap uninvited guests [126], Ab
could represent a first immune response against a
microbial invader in the brain. Interestingly, fungi
and the bacterial component lipopolysaccharide
have been found in post-mortem brains of AD
patients, especially in the area where Ab plaques
are present[124, 125, 127, 128], raising new
hypothesis of AD pathogenesis.
A theoretical framework integrating the current
hypotheses in AD and microbiota-mediated inflam-
mation would look as follows: intestinal lumen is
sensible to signals coming from microorganisms
and directly from the diet. These signals activate
inflammatory mediators in the gut mucosa and
submucosal layers, which can generate adaptive
responses through antimicrobial and active pep-
tides. The generated peptides can be secreted into
the lumen to help maintain homeostasis. Simulta-
neously, effector cells will secrete chemokines to
the bloodstream that are able to communicate to
the central nervous system (CNS) by and/or
through the BBB. In response to the gut signalling,
inflammatory cells in the brain can activate the
complement C1q, activate inflammatory receptors
such as RAGE and modulate deposition of Ab.
Nevertheless, the presence of gut metabolites and
microbiota-induced inflammation in the brain of
man require more research for confirmation and
further characterization (Fig. 3).
In conclusion, the microbiome is influenced by
factors such as the environment, the diet and the
Current and novel Alzheimer´s disease therapy targets / R. Loera-Valencia et al.
ª 2019 The Association for the Publication of the Journal of Internal Medicine 407
Journal of Internal Medicine, 2019, 286; 398–437
season of the year. All these parameters can be
used to improve the power of these studies to find
more specific signatures. Moreover, stable micro-
biota signatures have been identified that can be as
unique to individuals as fingerprints [129].
Regarding therapeutic opportunities, it is possible
in theory to modify the composition of the gut
microbiota to prevent or improve cognitive symp-
toms in AD. The most common strategy to induce
gut microbiota modification is the dietary supple-
mentation of probiotics—living microorganisms
that provide health benefits when ingested. In the
only intervention trial reported so far, a probiotic
containing Lactobacillus acidophilus, Lactobacillus
casei, Bifidobacterium bifidum and Lactobacillus
fermentum has been tested in Iran on severely
demented older patients in comparison to a
placebo. The probiotic group showed an ameliora-
tion in cognitive functions from baseline
(MMSE = 8.7) after 12 weeks of supplementation
(MMSE = 10.6), whereas the placebo group showed
a decrease in MMSE scores from 8.5 to 8.0 over
12 weeks. An impact was reported not only in
MMSE scores but also in blood markers of insulin
and lipid metabolism, suggesting that the probiotic
formulation has several beneficial effects [130].
Despite the above intriguing results, it is still
challenging to identify a universal AD gut micro-
biota signature and also a therapeutic composition
of microorganisms as a potential therapy.
Fig. 3 Possible pathophysiologic role of microbiota in Alzheimer’s disease. BBB, blood–brain barrier; BMAA,
b-Nmethylamino-L-alanine; HSV-1, herpes simplex virus type 1; LPS, lipopolysaccharide. From: Marizzoni et al. [119].
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Therefore, further studies on novel mediators of gut
microbiota-induced inflammation in blood and
CSF are the potential keys to develop therapeutic
strategies.
Restoring insulin action & glucose metabolism in AD: our short-term
perspectives
Besides the known effects of amyloid-b (Ab) and
hyperphosphorylated Tau protein in the central
nervous system (CNS) in AD, they may be also
important at the periphery[131]. For instance, Ab
may compete with insulin and bind to its receptors
at the periphery, impairing pancreatic b-cells and
leading to insulin resistance and glucose dys-
metabolism [132, 133]. This may in turn exacer-
bate Ab deposition [134, 135], creating a vicious
cycle of dysfunctional CNS insulin signalling,
oxidative stress and neuroinflammation, culminat-
ing in cognitive deficits [136]. Despite controver-
sial, this may also involve the hyperphosphorylated
Tau-induced destabilization of microtubules in b-
cells, blunting insulin secretion [137] and insulin-
mediated trafficking of glucose transporter-4
(GLUT4)-containing vesicles to the plasma mem-
brane. Hence, glucose uptake into skeletal muscle
and adipocytes is inhibited and type 2 diabetes
(T2D) may arise [138–140].
Insulin and its downstream signalling cascades
play a crucial role against CNS damage and dis-
ease. Besides the known regulation of brain glu-
cose/bioenergetic homeostasis [141–143], insulin
signalling protects against oxidative stress, (neuro)
inflammation and dysfunctional intracellular qual-
ity control mechanisms [144–147], rescuing synap-
tic/neuronal function [148, 149] and cognition
[150]. This downregulation of bioenergetic metabo-
lism in insulin-resistant brain may arise years
before the onset of clinical symptoms (possibly
during midlife), affecting Ab or Tau homeostasis
and rendering people (especially women) more
prone to dementia and AD [151–155]. Thus, AD
has been increasingly considered a metabolic dis-
order, also termed ‘type 3 diabetes’ [156].
Evidence for AD-related brain glucose hypometa-
bolism includes the slowdown in cerebral blood
flow due, for example, to brain vascular atrophy
[157]. This, together with the lower levels of GLUT-
3 and -4 in AD brain, may attenuate the glucose
uptake across the blood–brain barrier (BBB) and
its use by CNS [158, 159]. AD also inhibits brain
enzymes from glycolysis and Krebs cycle (e.g.
lactate dehydrogenase (LDH), aconitase, glutamine
synthetase, creatine kinase, pyruvate dehydroge-
nase (PDH) and alpha-ketoglutarate dehydroge-
nase (a-KGDH)) [160, 161], depending on disease
progression [162]. Besides the possible direct
impact of PDH inhibition in lowering the levels of
acetyl-coenzyme A, acetylcholine, cholesterol and
neurosteroidal hormones (e.g. oestrogen) upon AD
[163], these metabolic changes further associate
with mitochondrial alterations along disease pro-
gression [164]. In this perspective, Ab is widely
known to deregulate mitochondrial proteins,
blunting mitochondrial cytochrome c oxidase (or
complex IV) activity and oxygen respiration rate,
either centrally and/or peripherally (e.g. in plate-
lets) [165–168]. This may be also due to a reduction
in the neuronal expression of nuclear genes that
code for mitochondrial electron transport chain
subunits [169], or to a decrease in the number of
neuronal mitochondria [155]. Importantly, the
disruption between mitochondrial respiration and
energy metabolism in AD was also associated with
oxidative stress [156, 170], possibly due to activa-
tion of p38MAPK signalling and subsequent hip-
pocampal glutamatergic synaptotoxicity/death,
culminating in the AD cognitive deficits [170,
171]. Alternatively, disrupted mitochondrial
dynamics (fission and fusion) and trafficking upon
AD may hamper the development and maturation
of synapses [164, 172, 173]. Moreover, the corre-
lation between early deficits in synaptic mitochon-
dria and synaptic loss in AD [162, 174] reinforce
the notion that brain glucose (energy) hypometa-
bolism may constitute an early event in disease
pathogenesis, starting decades before its diagnosis
(probably during midlife) [175, 176]. This may
impair neuronal insulin signalling, creating a
vicious cycle of Ab-mediated and hyperphosphory-
lated Tau-mediated injury [177, 178].
Although this is not the aim herein, there are
extensive differences (even at the level of gene
expression) between male and female brain (meta-
bolism) upon ageing and/or AD [153, 179] that
may further condition the whole discovery/devel-
opment of successful preventive and therapeutic
strategies against the disease.
Opportunities in drug development in AD
The ‘charm’ of repurposing efficient anti-T2D drugs
to recover brain insulin signalling and glucose
metabolism in AD. The failures described above
point to the urgent need to unveil the precise
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aetiology and pathophysiological mechanisms of
AD, as these will be also crucial to discover more
accurate diagnostic and efficient therapeutic tools
[157, 180]. They also emphasize the need of
supporting Phase III clinical trials on strong and
accurate preclinical data and to tackle multiple
therapeutic targets [157]. Moreover, the refocus on
preventive strategies and/or drugs targeting the
prodromal or very early stages of AD (before the
onset of dementia) will hopefully maintain a longer
quality of life [157].
Amongst such promising therapeutic (and preven-
tive?) strategies in AD, one tempting target is the
rescue of brain insulin signalling and glucose
metabolism [157]. Accordingly, an increasing
attention has been given to the potential benefits
of repositioning efficient, commercialized anti-T2D
drugs to treat AD [181–184]. This hypothesis is
supported by the molecular mechanisms shared by
T2D and AD [183, 184]. This is also tempting due
to the potential targeting of preclinical/prodromal
AD, mild cognitive impairment (MCI), or at-risk
conditions (prevention), rather than just its later
stages [157, 183, 184].
The temptation of using biguanides (metformin)
against AD: a friend or foe?. Metformin is the
most efficient anti-T2D biguanide [183–185]. It is
relatively inexpensive and with a low risk of hypo-
glycaemia [183]. Metformin inhibits insulin-medi-
ated hepatic glucose production and promotes
peripheral glucose disposal by activating liver and
skeletal muscle AMPK signalling [183, 184]. Given
its good tolerability, metformin can be used as
mono- or multi-therapy at all stages of T2D [183].
Amongst its adverse effects are gastrointestinal
distress, hepatic dysfunction, congestive heart
failure, dehydration and alcoholism [183, 184].
Therefore, metformin must be used with caution in
elderly patients.
Preclinical data suggest that metformin may be
neuroprotective, probably by recovering brain
insulin action and energy metabolism [183–185].
Metformin also increased markers for mitochon-
drial biogenesis and fusion (e.g. Mfn2 and OPA1),
attenuated mitochondrial transition pore opening
and oxidative stress, protecting against apoptosis
and cognitive deficits [183–185]. It also modulated
lipid and protein synthesis, fatty acid oxidation
and promoted neurogenesis [183]. However, the
rescue in hippocampal JNK signalling and synaptic
markers achieved by metformin did not improve
cognitive function in obese T2D mice [186] and
even promoted hepatic mitochondrial dysfunction
and cell death [187].
Concerning its role in ageing and AD, metformin
decreased the risk for dementia in aged individuals
and improved cognition in AD patients [188, 189].
This may involve the attenuation in neuronal
insulin resistance and AD-like neuropathology,
most likely via AMPK-related regulation of APP
amyloidogenic processing; inhibition of mTOR and
subsequent autophagic/lysosomal removal of Ab;
and/or the stimulation of PP2A activity and
decreased Tau hyperphosphorylation [190, 191].
Given such promising data, according to Clini-
calTrials.gov, two Phase II clinical trials on the
effects of metformin administration in middle-aged
and aged obese patients with amnestic MCI
(NCT00620191), or in MCI and early AD patients
(NCT01965756) were recently completed and
results are awaited soon.
The potential of thiazolidinediones to tackle
AD. The main thiazolidinediones (TZDs) used in
T2D are Rosiglitazone, Pioglitazone and troglita-
zone [183]. Though TZDs are relatively expensive,
they are very efficient in the long-term manage-
ment of T2D [183, 184]. These drugs act as PPARc
agonists to promote the transcription of genes
related to lipid and glucose metabolism [192,
193]. More specifically, TZDs increase insulin-
induced glucose uptake (most likely via GLUT-1
and GLUT-4) and decrease lipid accumulation by
skeletal muscle, stimulate triglyceride storage in
adipocytes, hepatic fatty acid oxidation and inhibit
hepatic gluconeogenesis [184]. Amongst their
adverse effects are a possible weight gain and
increased risk of myocardial infarction [184].
Some neuroprotective effects were described for
TZDs, including a decrease in stroke-related dam-
age and neurological deficits in T2D mice [194].
Others suggested that TZDs-mediated reduction in
brain oxidative stress and rescue in STAT3/Wnt
signalling pathways may promote neuronal pro-
genitor cells proliferation and differentiation upon
T2D [195]. This, together with a protection against
amyloidogenic processing of APP, Tau hyperphos-
phorylation, neuroinflammation and Ab-induced
neuronal insulin resistance may account for the
recovery in memory and cognitive performance in
patients and rodent models [183, 184]. In line with
this, in a randomized clinical trial, Rosiglitazone
improved cognitive function in mild to moderate AD
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patients [196], whereas in a Phase III study the
drug did not show beneficial effects in AD patients,
and the long-term use of thiazolidinediones did not
attenuate the risk for AD [197].
According to ClinicalTrials.gov, a Phase III clinical
trial is currently analysing the potential of Piogli-
tazone as a b-secretase inhibitor (TOMMORROW;
NCT01931566) in people aged 65-83 years, at risk
of MCI due to AD. A masked extension of this study
(NCT02284906; phase III) is planned with 316
individuals with an MCI diagnosis due to AD that
complete the TOMMORROW study.
Is it still worthy to evaluate (intranasal) insulin for
AD treatment? The pros and cons. . .. Insulin has
been increasingly used in T2D, not only for blood
glucose management but also to prevent its
chronic microvascular complications and death
[198]. However, some controversy persists on its
efficacy, which may be lost upon T2D progression.
Physiologically, brain insulin signalling promotes
synaptic remodelling and memory formation [199,
200]. We also found that restoring insulin and IGF-
1 signalling recovered both peripheral and brain
glucose metabolism, and motor function in vitro
and in vivo in Huntington’s disease models [201–
203]. Moreover, insulin decreased synaptic Ab
accumulation, oxidative damage and mitochon-
drial dysfunction [143, 204]. This was accompa-
nied by a protection against Ab-induced neuronal
insulin resistance [205, 206]. However, associated
with insulin administration is the high risk of
recurrent hypoglycaemia, which has been increas-
ingly related to neuronal dysfunction/death and
cognitive deficits [207, 208]. But since restoring
brain insulin signalling constitutes a promising
approach against AD, an alternative could be the
potential use of intranasal insulin herein.
Intranasal insulin promoted brain insulin sig-
nalling in AD, without affecting blood insulin or
glucose levels [209]. Clinical trials involving MCI or
early AD patients showed that intranasal insulin
improved brain glucose metabolism and stabilized
or even rescued their memory and cognitive deficits
[199, 210, 211]. According to ClinicalTrials.gov,
results are awaited from two recently completed
Phase II/III and II clinical trials on insulin (SNIFF;
NCT01767909) and glulisine (a rapid-action insu-
lin analog that regulates glucose metabolism and
counteracts Ab) (NCT02503501), involving middle-
aged and aged MCI or mild AD individuals. Possible
limitations to the use of intranasal insulin for AD
treatment could be the generalized increase in
brain insulin levels and its possible adverse con-
sequences on brain regions (like hypothalamus)
that control, for example, water and food intake
[212].
The increasing therapeutic potential of incretin
drugs in AD. -Dipeptidyl peptidase-IV inhibitors—
Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin,
Alogliptin, Tenegliptin, Dutogliptin and Gemigliptin
are the main dipeptidyl peptidase-IV (DPP-IV)
inhibitors used to treat T2D [183, 184, 213]. DPP-
IV inhibitors are oral small molecules that blunt the
degradation of native GLP-1 by the aminopeptidase
DPP-IV, increasing its half-time and circulating
levels, together with the attenuation of glucagon
effects [213–215]. DPP-IV inhibitors are well
tolerated and can be used either as mono- or
multi-therapy [184, 213]. Apparently, these drugs
do not affect gastric emptying, body weight or
cardiovascular function and present a low risk of
hypoglycaemia [184, 213]. However, their efficacy
may be lost upon T2D progression [216].
Sitagliptin attenuated mouse hippocampal AD
neuropathological hallmarks, improving also
acetylcholine and adiponectin receptor levels in
T2D rat brains [217, 218]. Sitagliptin and Vilda-
gliptin also decreased peripheral T2D and oxidative
stress markers and rescued learning and memory
deficits in insulin-resistant and T2D rats [217,
219, 220]. Vildagliptin also decreased the levels of
Ab, hyperphosphorylated Tau and neuroinflamma-
tory markers, and rescued memory deficits upon
AD [221]. However, it is still debated whether DPP-
IV inhibitors can cross the blood–brain barrier and
exert direct effects in the brain or if their effects are
mostly peripheral [184, 213]. Further research is
needed before including DPP-IV inhibitors into
clinical trials in AD.
-GLP-1 receptor agonists—Exendin-4, liraglutide
and lixisenatide are the most used GLP-1 receptor
(GLP-1R) agonists in T2D [183, 184, 213, 222].
They act as incretin mimetics, promoting insulin
secretion in a glucose-dependent manner to over-
come insulin resistance [183, 213, 222]. Besides
their minimum risk of hypoglycaemia, GLP-1R
agonists have also potent, long-lasting anti-obeso-
genic effects, possibly via a hypothalamic-regu-
lated decrease in appetite and food intake [213].
They also showed benefits in blood pressure,
cholesterol and triglycerides levels, as well as in
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cardiac function upon T2D [213]. Though the
mechanisms involved herein remain poorly known,
they may rely on a decrement in markers for
cardiovascular risk (as IL-6, TNFa), endothelial
dysfunction, oxidative/endoplasmic reticulum
(ER) stress and inflammatory pathways [213].
Interestingly, liraglutide promoted GLUT4 translo-
cation in mouse skeletal muscle via cAMP sig-
nalling and may thus affect glucose uptake and
metabolism [223].
GLP-1R agonists are known to readily cross the
blood–brain barrier and directly affect the brain,
where they may act like neurotrophic factors [213,
222]. Mounting evidence point towards a neuro-
protective role of GLP-1R agonists against in vitro
and in vivo AD [222, 224, 225]. Specifically, these
drugs attenuated Ab, APP and hyperphosphory-
lated Tau levels, neuroinflammation, oxidative/ER
stress and neuronal death in AD [213, 222, 224,
225]. These were mirrored by increased insulin
degrading enzyme and insulin signalling, which
may recover glucose metabolism, synaptic trans-
mission/plasticity, neurogenesis and, ultimately,
memory and cognitive performance [178, 213, 222,
224, 225]. Similar results were recently reported
with lixisenatide [226].
Results are awaited from the two recently com-
pleted clinical trials on exendin-4 (Phase II;
NCT01255163; involving MCI or mild AD individu-
als, aged ≥ 60 years) and liraglutide (Small ran-
domized; NCT01469351; involving early-onset AD
patients), as well as from a recently started large-
scale, phase II clinical trial on liraglutide in early AD
patients, aged 50–85 years (ELAD, NCT01843075).
The novel and still unexplored anti-AD therapeutic
potential of SGLT2 inhibitors. The main SGLT2
inhibitors used to treat T2D are empagliflozin and
dapagliflozin. Although they exert their glucose-
lowering effects mainly through a novel, insulin-
independent mechanism (via increased renal gly-
cosuria), one cannot exclude the increase in
peripheral insulin sensitivity, GLP-1 levels and/or
b-cell function [227–232]. This may be accompa-
nied by decreased leptin levels, endothelial dys-
function, oxidative stress and inflammation
markers, ultimately reducing blood pressure and
body weight [233]. Thus, SGLT2 inhibitors may
optimally reduce the long-term complications asso-
ciated with T2D, with a low risk of hypoglycaemia
and hypotension [230, 234]. Although little is
known on its neuroprotective role, empagliflozin
may protect obese T2D mice against brain oxida-
tive stress and DNA damage probably via the
recovery in serum insulin levels and vascular
function, ultimately rescuing their learning and
memory function [235, 236]. Additionally, dapagli-
flozin-mediated attenuation of retinal capillary
hyperperfusion, arteriole wall thickening and
microvascular remodelling in T2D were followed
by a decrease in brain markers for oxidative stress,
inflammation and apoptosis [235, 237, 238]. This
was further accompanied by an improved insulin
action, mitochondrial function, synaptic density/
plasticity, neurogenesis and in learning and mem-
ory in T2D patients and animal models [235–238].
To our knowledge, there are no current clinical
trials on the use of SGLT2 inhibitors to tackle AD.
In conclusion, one can hypothesize that either by
ameliorating peripheral insulin action and glucose
homeostasis and/or by crossing the blood–brain
barrier and exerting similar effects in the central
nervous system, anti-T2D drugs from the different
classes may represent promising therapeutic
approaches to tackle AD (Fig. 4).
Restoring brain cholesterol metabolism by CYP46A1 gene therapy
Increasing evidence demonstrates the role of brain
cholesterol in the physiopathology of neurodegen-
erative disease particularly in Alzheimer’s disease
and Huntington’s disease[239, 240]. Brain con-
tains a particularly high portion of total body
cholesterol, since our brain represents 2% of our
body weight, but contains 25% of total cholesterol.
Besides the important (70%) myelin fraction, brain
cholesterol is a major constituent of neuronal
membranes and plays crucial role in synaptic
function and neuronal survival.
Increasing arguments link brain cholesterol meta-
bolism and AD. Tangles of Tau are observed In
Niemann–Pick-C, a genetic disease of cholesterol
metabolism, confirming the direct connection
between dysfunction of cholesterol in the brain
and the tangles of Tau. The role of ApoE, the main
cholesterol transporter in the brain, and of the
ApoE4 allele has been long recognized as the main
risk factor (after age) for Alzheimer’s disease [6].
More recently, GWAS analysis has identified sev-
eral genes of lipid metabolism, like SORL, ABCA7
and CLU in association with AD [241]. Cholesterol
increased concentration has been evidenced in the
brain of AD patients. The role of statins (inhibitors
of HMGCoA reductase key enzyme of cholesterol
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synthesis) is still debated. However, a recent
retrospective study on 400 000 patient receiving
long-term treatments by statins evidenced a link
between a decreased frequency of Alzheimer’s
disease to chronic administration of statins, a link
varying upon sex, ethnicity and molecules [242].
Yet, the discussion on statins and cognitive decline
in AD remains open [243].
Cholesterol is directly associated with plaques and
tangles. In vitro and in vivo studies have shown that
increased cholesterol content in membranes is
associated with increased A-beta production. Con-
versely, decreased cholesterol in the membranes
favours the nonamyloidogenic pathway of APP
processing [244].
Cholesterol cannot cross the blood–brain barrier
(BBB), and brain cholesterol is produced in situ,
mostly by astrocytes in adults. It is then trans-
ported to neurons by APOE, which are the major
consumers of the generated cholesterol. To some
extent, cholesterol is also produced by synthesis
in neurons and this is an important part of the
brain cholesterol homeostasis. Cholesterol is
excreted from the brain mostly after transforma-
tion into 24-hydroxycholesterol (24-OH), that can
freely cross the BBB and is metabolized in the
liver. 24-OH is produced by CYP46A1, a cyto-
chrome enzyme specifically expressed in the brain
[245, 246]. CYP46A1 is a key enzyme of brain
cholesterol metabolism. Not only CYP46A1 allows
most cholesterol efflux from the brain, it also
activates the whole pathway of cholesterol meta-
bolism, the so-called mevalonate pathway (Fig. 5)
and represents an important stress response
factor to noxious stimuli like ageing, toxic protein
aggregates, disease conditions like AD [247, 248].
CYP46A1 was shown in response to stress, to
induce the relocation of Trkb in plasma mem-
branes, leading to its activation and to postsy-
naptic stress response signalling, a pathway that
could be associated with improved cognition and
synaptic plasticity [247].
The decrease in CYP46A1 function in normal
mouse hippocampus, using AAV- CYP46A1 shRNA
delivery is associated with cholesterol accumula-
tion in cell membranes and strong neuronal toxi-
city leading to severe endoplasmic reticulum stress
and neuronal death with hippocampal atrophy.
Interestingly a reduction of only 30 to 50% in
CYP46 levels induces amyloid beta accumulation
and hyperphosphorylation of Tau protein in the
hippocampus, a phenotype resembling Alzheimer’s
disease. CYP46A1 inhibition in AD mice with
amyloid pathology leads to accelerated toxicity
with major amyloid accumulation, rapid neuronal
death and seizures, evidencing the toxic loop
between cholesterol metabolism impairment and
amyloid production [249, 250].
On the contrary, CYP46 overexpression in AD
models improves cognition and decreases pathol-
ogy in the brain. Injection of an AAV vector coding
for the enzyme CYP46A1 restores cholesterol
Fig. 4 Type 2 diabetes drugs
for treating AD. Strategies to
improve insulin actions in AD
brains could act by
ameliorating peripheral insulin
action or cross directly into the
CNS to restore glucose
homeostasis.
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metabolism, decreases amyloid beta accumulation
and plaque formation in the different AD models
[249, 251] (Fig. 6). Importantly, this beneficial
effect of AAV-CYP46A1 delivery is demonstrated
not only in three different amyloid models but also
in Tau22 mice [252]. Dendritic spine density are
restored, together with electrophysiological param-
eters (LTC), contributing to the correction of mem-
ory deficits in these mice. In parallel, results from
studies in Huntington mouse model demonstrated
that overexpressing CYP46A1 restores deficient
cholesterol metabolism, behaviour deficits and
neuropathological hallmarks confirming the link
between brain cholesterol impairment and neu-
ronal function[253].
A gene therapy approach based on AAV-CYP46A1
braindelivery is thusapotentiallypowerful strategy,
acting both on the amyloid and the Tauhallmarks of
the disease. Feasibility and safety of the procedure
were demonstrated in monkey brain (unpublished
results). Improvement of AAV vectors able to effi-
ciently target brain neurons after intrathecal or
intravenous injection should help the development
of such therapeutic approaches. Increased 24-OH
cholesterol in CSF could be evaluated as a biomar-
ker of mechanism to evidence the efficacy of the
therapy.AAVvectorshavebeenapproved forhuman
use and several clinical trials using AAV vector
delivery to the brain have been performed or are
ongoing [254]. These vectors allow long-lasting
expression with only one injection.
A first application in human patients could be in
severe familial forms of Alzheimer’s disease.
Patients can be diagnosed and treated at very early
stages of the disease, when a therapeutic benefit
could be expected.
Molecular mechanisms behind glucose and cholesterol metabolism
for developing AD
Several reports have looked at patients with altered
cholesterol metabolism in the brain and their
susceptibility to developing AD [255–259], and in
the last two decades, BBB-permeable cholesterol
metabolites (known collectively as oxysterols) have
been identified as possible mediators of cholesterol
effects in the brain [248, 260–264]. The main
oxysterol exchange between the brain and the
circulation is between 24-hydroxycholesterol (24-
OH), which is originated in the brain as discussed
before, and 27-hydroxycholesterol (27-OH) which
is generated by the activity of the enzyme CYP27A1
in the periphery [248, 261, 263, 264].
Excessive 27-OH has been related to AD [265,
266] and to PD [267–269]. It’s also associated to
breast cancer [270] and to a genetic disease called
hereditary spastic paraplegia of the fifth type
(SPG5) where a mutation causes a loss of function
of CYP7B1, an enzyme that degrades 27-OH, so
these patients have ten times more 27-OH than
normal individuals [271, 272]. Nevertheless, indi-
viduals without this mutation can also show
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elevated levels of 27-OH in the blood, which
correlate to 27-OH levels in the CSF [273]. In
these patients, elevated 27-OH levels correlated
negatively with glucose uptake in the hippocam-
pus, posterior cingulate and cerebellum as mea-
sured by 18F-FDG PET. The patients could be
stratified in two groups: the first one would have
more than 1 ng/mL 27OH in CSF and a global
decrease in brain glucose uptake, whilst the
second group with less than 1 ng/mL 27-OH in
CSF with decreased glucose uptake only in the
hippocampus and posterior cingulate.
Preclinical models have already provided informa-
tion on the mechanisms of elevated 27-OH influ-
ences glucose metabolism in the brain,
contributing to cognitive decline in AD. High-fat/
high-cholesterol diet (HFD) in aged mice led to
decreased ARC protein levels in the hippocampus
as well as reduced NMDA receptor activity [274]. As
mentioned previously, cholesterol does not cross
the blood–brain barrier and these studies pointed
to 27-OH as a mediator of the negative effects of
high-fat diets in brain function markers. Moreover,
HFD leads to cognitive impairment in mice and
knocking out Cyp27A1, the enzyme converting
cholesterol to 27-OH, protects mice against HFD-
induced cognitive deficit [275].
Alterations of the renin-angiotensin system in the
brain in AD
In an effort to identify the mechanisms by which
high levels of 27-OH produce neuronal damage, we
reported high levels of 27-OH increase the renin-
angiotensin system activity in HFD fed mice (Fig. 8)
[276]. These results were proven translatable when
found that patients with MCI and AD also present
increased angiotensin (AGT) and angiotensin-con-
verting enzyme (ACE) in the brain [277]. Going back
to the animal models to clarify the mechanisms of
action of 27-OH in the brain, the Cyp27TG mice
were used, a transgenic mouse model overexpress-
ing CYP27A1 to produce 5 times more 27-OH
systemically. These animals also show cognitive
impairment at 12 months old together with reduced
glucose uptake in the brain [273, 278]. The mech-
anisms leading to reduced glucose uptake in these
mice is mediated by an over-activation of the RAS
system, leading to an imbalance between the
angiotensin isoforms AngIII and IV [273]. The
balance between these forms is also modified by
the catabolism of AngIV by aminopeptidases, which
are modulated importantly by 27-OH, particularly
aminopeptidase-A (AP-A) and aminopeptidase-N
(AP-N). In CYP27TG brains, elevated 27-OH
increases AP-N, which cleaves AngIV thus decreas-
ing its levels. AngIV under physiological conditions
downregulates the abundance of insulin-regulated
aminopeptidase (IRAP) in the brain [279], but under
high 27-OH levels, AP-N degrades AngIV allowing
increased IRAP activity [273].
Elevated 27-OH levels not only increase IRAP
activity but also decrease the levels of the glucose
transporter GLUT4, which is regulated negatively
by AngIII. In CYP27TG brains, Ang III is elevated
due to increased AP-A activity (converting AngII to
AngIII), which in turn downregulates GLUT4 [273].
Fig. 6 Gene therapy on
CYP46A1. The first panel
shows the site of injection with
the viral vector carrying an
overexpressing copy of
CYP46A1 for gene therapy.
Neuronal transfection of
CYP46A1 can be detected
(green) in neurons in the
hippocampus (red) as shown
by the upper pannels. After
gene therapy treatment with
CYP46A1, amyloid plaques in
the hippocampus are reduced.
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Together with increased IRAP activity, GLUT4
downregulation leads to reduced glucose uptake
by neurons (Fig. 7). These mechanisms have been
confirmed in vitro by knock-down experiments and
they explain the alterations observed in patients
with altered RAS markers in the CSF.
Taken together, these results point CYP27A1 as a
druggable target to prevent the effects of peripheral
hypercholesterolaemia in the blood, in opposition
to statins or ACE inhibitors. A recent clinical trial
with atorvastatin in SPG5 patients did not decrease
27-OH levels in patient0s CSF, whilst effectively
decreasing them in the blood together with choles-
terol, meaning that statins cannot effectively nor-
malize 27-OH in the brain in the short term [272].
CYP27A1-specific inhibitors, such as anastrozole,
have been proposed as therapeutics for AD [280];
however, to our knowledge, no clinical trial is
testing the effect of these compounds in AD risk
or cognition.
Insulin aggregation in AD
The reduced glucose uptake mediated by high 27-
OH levels might pose a link between cholesterol
and glucose metabolism alterations as important
players in the development of AD. We recently
reported that insulin aggregates and accumulates
in neurons with hyperphosphorylated Tau from
humans [151]. The finding was not only exclusive
of AD but also of other tauopathies, having insulin
resistance as a common denominator for most
cases. Moreover, neurons with aggregated insulin
show decreased insulin receptor levels and neu-
roblastoma cells overexpressing Tau show
decreased GLUT4 expression levels (Fig. 7). This
is in line with other papers suggesting similar
relationships between insulin resistance and Tau
[281, 282]. Whilst some reports exist linking high
cholesterol with hyperphosphorylated Tau [267,
283, 284], the mechanistic link between glucose
and cholesterol metabolism underlining neurode-
generation needs further research. Yet, it is highly
possible that such a link exists and plays a major
role not only in AD but also in other tauopathies
and in PD.
This underlines the importance of redirecting
research efforts to classify AD patients according
to specific biochemical pathway imbalances they
might present in order to better design clinical
trials for treating or modifying AD progression.
Further research should focus on topics of insulin
metabolism, cholesterol and lipid dynamics in the
brain and their relationship with parallel patholo-
gies such as diabetes that could lead to earlier
hallmarks of AD manifestation, new targets for
drug development and new therapeutic strategies
to treat neurodegenerative diseases.
Amyloid beta in Alzheimer’s disease: an overview
Ab load in the brain correlates well with the degree
of dementia, where it becomes more neurotoxic
after polymerization [285, 286]. Most familial cases
show increased Ab isoforms with 42 to 43 amino
acids in the CSF [287–290]. Persons with Down’s
syndrome also present an over-production of Ab
and an early onset of AD [287]. Transgenic mice
overexpressing Ab are available for the investiga-
tion of the AD pathogenic mechanisms. Many of
these models develop AD-like lesions and show
impaired memory [291–294]. Nevertheless, overex-
pression of APP in mice has received criticism due
to the difference from physiological levels observed
in human brains [295, 296]. Because of this, novel
models closer to human brain biochemistry aim to
uncover mechanisms with more translational pro-
files [297–299].
In the amyloid cascade model, Ab42 aggregates in
the presence of binding proteins such as ApoE, as
well as with metal ions, leading to plaque formation
[15, 241, 300]. Downstream, the cascade leads to
Tau aggregation, inflammation, oxidative stress
and ultimately neuronal death [301]. These path-
ways are rather clear at least for the familial cases.
Now with the genome-wide association studies
(GWAS), we have several new prospects coming
up, but still, it is a scientific consensus that Ab
processing and Tau hyperphosphorylation are key
components of AD pathology [302].
Upstream, we have more new pathways that have
been elucidated, mainly by the GWAS [241]. These
are the glucose metabolism, the cholesterol meta-
bolism, inflammation, intracellular membrane,
and vesicle recycling and oxidative stress [4, 241,
303, 304]. These pathways and targets will be
useful in the future and could potentially lead to a
combined therapeutic strategy.
Positron emission tomography (PET), biomarkers
and early diagnosis in AD
Another important part is the biomarkers. Amyloid
accumulation comes early in the disease, long
before clinical diagnosis [305]. With PET scanning,
it is possible to see the amyloid assemblies in the
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brain [306]. Today other markers are known, such
as inflammatory markers in PET imaging coming
up years before the diagnosis [307–309]. Today
with the help of biomarkers, we can put the
diagnosis 10-15 years earlier in patients. Recently,
a group from the National Institute on Aging and
Alzheimer’s Association (NIA-AA) have proposed a
framework of preclinical AD based on biomarkers
Fig. 7 Metabolic effects of elevated 27-OH in the brain. Elevated cholesterol in the periphery cannot cross the BBB.
CYP27A1 converts peripheral cholesterol to 27-OH, which is able to cross the BBB into the brain and inside cells. In neurons,
increased levels of 27-OH dysregulate the renin-angiotensin system (RAS), by acting directly or indirectly over the glucose
transporter GLUT4 and the insulin-regulated adaptor protein (IRAP). This leads to a decreased glucose uptake and reduces
the metabolic activity of neurons, contributing to cognitive decline. Moreover, insulin aggregation also decreases glucose
uptake. Insulin aggregation reduces dramatically its signalling and these effects are not fully understood. A link between
RAS system and insulin aggregation also remains unknown, but it could involve IRAP signalling, AngIV derived peptides
(produced by AP-N and AP-A activity), or through reduction of blood flow in brain vessels.
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capable to determine the state of the pathology
[310].
Many research efforts aim to find specific patterns
between Ab accumulation in the human brain and
AD progression. Patients with MCI have shown that
converting to AD implies PIB retention in the
frontal cortex 2–3 years before the symptoms
appear [311]. Additionally, stable PIB retention
after 2 years in human brains can be used to
pinpoint the stage before the onset of cognitive
decline in AD [305]. Yet, resolution limits on PET
scanning do not allow identifying small changes in
Ab accumulation in the preclinical stage that might
be important for preventive or intervention strate-
gies. Because of this, more studies are required to
complement imaging data to accurately diagnose
early stages of AD.
Clinical trials and immunotherapy in AD
There are clinical trials ongoing with molecules
affecting the Ab metabolism by either decreasing
their production, inhibiting their aggregation or
increasing the clearance [13, 14]. Ongoing studies
in the field of amyloid-related approaches are
clearing out the Ab monomers, forming dimers,
pentamers, oligomers, fibrils, diffuse plaques and
senile plaques using antibody therapies. Some
antibodies such as aducanumab, even reduce the
senile plaques [312].
Since 2013, many trials have been withdrawn due
to lack of effects, most notably the anti-amyloid
antibody solanezumab [313] and the BACE1
inhibitor verubecestat [314]. The negative out-
come in these trials has led to an extensive
revision of the amyloid cascade hypothesis [16,
17, 315, 316]. These clinical trials have provided
data supporting previous hypotheses proposing
dementia as a product of the cellular phase of AD
[19], which comprise pathological processes
involving targets in microglia, astrocytes, oligo-
dendrocytes and vasculature before clinical man-
ifestations. Still, several aspects of the amyloid
cascade hypothesis remain to be tested, such as
the therapeutic relevance of clearing insoluble
amyloid versus preventing its production and
accumulation [17].
There is great interest in the immunotherapy
approach as a therapeutic option for AD, which
comprises the active immunotherapy, also called
vaccination [317], and the passive immunotherapy
[318]. For active immunotherapy, the immune
system is stimulated to produce antibodies against
Ab [319]. For passive immunotherapy, preformed
antibodies are humanized and injected into the
individuals with advanced AD [320]. Passive
immunization protocols require a repeated infu-
sion of the stimulus for the remaining lifespan of
the patients. The produced antibodies pass in
minute fractions into the brain and bind to fibrils,
oligomers and plaques preventing aggregation
and/or improving clearance. A promising
immunotherapy for AD therapeutics is AADvac1,
a vaccine against pathological Tau. For this vac-
cine, the phase I results of the FUNDAMANT study
(NCT02031198) have been published [321, 322].
The latest report showed slower atrophy in the
hippocampus in patients with high titers of anti-
body response and less cognitive decline.
Many clinical trials aiming at controlling the amy-
loid cascade propose diverse strategies and targets,
but so far, there is no consensus about a universal
target or approach for any form of AD.
Studies performed in Sweden, working with Novar-
tis as the sponsor yielded an active immunother-
apy against Ab using the CAD106, a small six-
residue Ab fragment recognized by B cells, admin-
istered together with an adjuvant of viral origin
[337, 340]. In order to have a clinical effect, a
specific concentration of the IGG A-beta titer is
required. After three or four injections, produced a
significant antibody titer; however, it was not
sustained long enough to induce a therapeutic
antibody response. A recent phase II study with
CAD106 showed target engagement and tolerabil-
ity; however, no improvement in MMSE scores was
obtained, possibly because of the small size of the
control cohort (14 patients) [332].
Swiss researchers created aducanumab, an inter-
esting antibody under BIOGEN development. Adu-
canumab is an antibody derived from healthy
elderly subjects with no decline in cognition and
from cognitively impaired elderly subjects with an
unusually slow decline rate. From these subjects,
memory B cells were isolated from lymphocyte
libraries and their produced antibody screened for
their ability to bind to Ab, in a process known as
reverse translational medicine [341]. In a very late
phase I study with its highest doses, aducanumab
could reduce Ab levels by 90%, as shown by PET
imaging [342]. Currently, aducanuab is in phase III
clinical trials for early AD with the ENGAGE
(NTC02484547) and EMERGE (NCT02484547)
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studies. Discussion from previous clinical trials
has pointed out that the main challenges to over-
come for aducanumab are to inhibit amyloid
aggregation avoiding cerebral angiopathy, and
achieve improvement in cognition [343, 344].
Recently, EISAI published positive results with the
antibody from BIOARCTIC, used in the clinical trial
phase IIb for BAN2401, a protofibril selective
amyloid beta antibody [323, 252]. The results for
BAN2401 came after a trial at 18 months in early
Alzheimer0s disease in a cohort of 856 patients. The
analysis of the results showed slowing in clinical
decline, which was dose dependent, together with
the reduction of Ab [345].
Chaperones and mitochondria: new and old options
for AD therapeutics
Another approach to AD treatment is to inhibit
protein aggregation using chaperone proteins. Evi-
dence shows the intraneuronal amyloid is also
important enough to affect the parenchymatous
amyloid inside the brain [297, 346]. Chaperones
transport amyloid into the mitochondria, inducing
neurotoxicity [347] and if we could inhibit that
transport, it would be possible to preserve
Table 1. Advantages and disadvantages of passive and active immunotherapies for AD
Advantages Disadvantages Cost
Passive immunotherapies
Aducanumab [312]
Solanezumab [313]
BAN2401[323]
Increased control of epitope
binding affinity [324]
Require continuous
reinforcement of the
immunization [325]
High
Due to the need to design,
generate and humanize
antibodies [326]
Possible to stop therapy if
secondary effects are found
[327]
Increased risk of oedema/
micro bleeds due to repeated
infusion [328]
Modification of antibodies is
possible to improve efficacy
[329]
Longer time is required to
reach effective antibody titers
[323, 252]
Better for targeting Tau
oligomer isoforms [330]
Does not require the host
immune system. Elderly
patients may benefit [331]
Active immunotherapies
CAD106 [332]
AADvac1 [321]
Slightly different epitopes can
be recognized for each
individual, tailoring antibody
response [320, 333, 334]
Reduced control over epitope
choice and specificity [324]
Lower than passive
immunotherapies
The host produces own
antibodies [332, 335–337]
Fewer treatments needed to
achieve therapeutic effect
[338]
Difficult to reverse immune
response if secondary effects
are found [325]
Reduced risk for allergic
reactions to foreign molecules
[338]
Elderly patients may have
hypo-responsiveness to
immunization [339]
A better candidate for early
prophylactic approach
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mitochondrial function and save the synapses in
these nerve cells. On the other hand, chaperones
can also help increase the solubility of Ab. BRI-
CHOS is a conserved domain in proteins with
proposed chaperone activity and it has been
related to amyloidosis and dementia in the British
and Danish familial cases [348]. Expression of
BRICHOS in the brain prevents toxicity in Droso-
phila Ab models [349] and in APP mice [350]. In
prematurely born children with a collapse of the
lungs, BRICHOS is used as lung surfactant and
applied in form of aerosol [351, 352]. We have
difficulties in preclinical models, as the peptides
forming the chaperones do not cross the blood–
brain barrier. A promising solution to solve this
problem is the focused ultrasound therapy, which
employs controlled high-frequency ultrasound
pulses to shortly disrupt the BBB and allow
passage of bigger molecules into the brain [353].
Other approaches make use of native BBB trans-
porters such as transferrin-1, which can actively
pass molecules from the plasma into the brain
[354, 355].
Considerable research in AD is focusing on synap-
tic function, where mitochondria might underlie
one of the molecular pathways for neurodegener-
ation. Dimebon is a small molecule approved for
human use as an antihistamine [356]. Reports of
neuroprotective effects in models for AD led to a
first randomized clinical trial that was successful
even in terms of MMSE score improvement, daily
life activity and global cognition [357]. However,
the following phase 3 clinical trial (CONNECTION,
NCT00675623) for dimebon terminated early due
to lack of efficacy. One of the mechanisms of action
of dimebon is to inhibit mitochondrial pore open-
ing, increasing the membrane potential of the
mitochondria and improving ATP synthesis [358].
Since mitochondrial dysfunction is strongly asso-
ciated with ageing and AD, it is logical that small
molecules restoring mitochondrial function will
serve largely as part of future AD therapies.
In summary, several different dementia disorders
involve different protein aggregation profiles. Our
latest data support the claim that oligomers are
more toxic than fibrils for neurons. Although it is
very possible that the amyloid beta-peptide is
somehow involved in the different stages, we will
need a combination therapy. Many trials are ongo-
ing for lowering Ab levels in either the production or
the aggregation or increasing its clearance. More-
over, similar approaches will give rise to therapies
for amyloid diseases in other organs such as the
heart and kidney, as well as in the peripheral
nervous system [359]. There is still a lot to do, but
what the scientific community and society must do
first is to re-stimulate public and private interests
in going back to basic science if we are to have a
pharmacological treatment strategy as early as
possible.
Tauopathies
In late stages of AD, we have an end-stage picture
of the disease where amyloid deposits are formed,
together with neurofibrillary degeneration, mean-
ing extracellular Ab and intracellular Tau. How-
ever, as mentioned before, early in the process,
intracellular Ab might be more toxic than the
extracellular one. We also know that Tau can be
secreted in the extracellular space.
With our current knowledge, the amyloid cascade is
likely to be more complicated than initially
described. The linear cascade of events leading to
the formation of Ab oligomers, aggregation, and
maybe propagation may not be so simple. Does Tau
pathology fuel this amyloid cascade? Does the amy-
loid pathology facilitate Tau secretion and propaga-
tion? Finally, in the amyloid cascade hypothesis,
inflammation arrives at the end. However, since
there are already early extracellular proteins aggre-
gating, inflammation is likely to be present at the
beginningofADassuggestedby several studies.Our
understanding of the sequence of events has been
hampered by the fact that there are not truly faithful
animal models of AD for research. Current models
mimic either amyloid pathways or Tau pathways.
Some studieshave attempted to showa link between
amyloid and Tau pathways [360]. This work shows
the possible interaction of both systems and also
including the idea of prion-like propagation and
seeding. Still, we do not know the real links between
amyloid and Tau pathways. For example, in several
GWAS [361–364], there are a number of genes
identified like PICALM, BIN1, PPK2B. These genes
are involved in Tau-mediated synaptic dysfunctions
but also in APP metabolism and Ab clearance,
meaning that some of these genes are really at the
border between amyloid and Tau pathologies, and
thus research has to focus on them.
According to Braak stages, it is well considered
that neurofibrillary tangle pathology starts within
the hippocampal formation. Then it goes to the
temporal area, then to polymodal association
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areas, unimodal association and finally the entire
cerebral cortex [386]. Recently, researchers pro-
posed a mechanism of prion-like propagation,
meaning that these Tau aggregates behave like
the prion proteins. In this way, Tau tangles induce
normal proteins into conformational changes lead-
ing to aggregation. More research focused on this
mechanism has shown incremental evidence sup-
porting this hypothesis.
It is logical to propose targeting Tau and Ab
together with other targets, since Tau is the main
component of aggregates leading to neurodegener-
ation. Nevertheless, these features represent the
end stage of the disease. Does it mean there are
other players in the initial process? For Ab, it is
likely because a mutation in APP is sufficient to
cause AD. For Tau, it is more complicated. The
presence of a mutation in Tau implies neurofibril-
lary degeneration without amyloid beta. Therefore,
it means that by itself, aggregated Tau is toxic but
does not lead to amyloid aggregation. In fact, Tau
protein does not only aggregate in AD but also in
other neurodegenerative disorders.
Tau biology is complex due to the presence of six
Tau isoforms in the human brain. They are gener-
ated by alternative splicing from a unique gene
MAPT located on chromosome 17. In the human
brain, these six isoforms are in equal ratio of
isoforms having three (3R) and four microtubule-
binding domains (4R). Nevertheless, this ratio is
modified amongst tauopathies showing different
aggregation profiles (Table 2). In addition, these
proteins go through posttranslational modification
such as glycosylation, phosphorylation, oxidation,
acetylation, and truncation. These posttransla-
tional modifications and truncation may facilitate
Tau aggregation even if the mechanisms are still
unclear.
Thus, Tau is not only found in Alzheimer’s disease,
it is also found in progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), argy-
rophilic grain disease and some patients present-
ing with frontotemporal lobar degeneration.
However, Tau aggregates display different regional
and laminar distributions, different morphologies
and different molecular characteristics. In fact,
amongst these disorders, aetiologies are also dif-
ferent. Head trauma is a risk factor since Tau
pathology is also found in traumatic brain injury
like dementia pugilistica. It has also been reported
in autistic children with self-injury behaviour.
Therefore, Tau aggregation is not only related to
ageing but to other factors that might differ from
those belonging to AD. Another aetiology may be
infectious agents like virus. Measles and Spanish
flu viruses have been described to lead to cerebral
Tau aggregation in subacute sclerosing panen-
cephalitis and postencephalitic parkinsonism
respectively. Therefore, infections may also trigger
Tau aggregation. Other metabolism dysfunctions,
as encountered in Niemann–Pick’s disease type C
(hereditary disorders with lysosomal lipidosis) and
PSP (caused either by industrial waste or by
mitochondrial toxins), also show Tau aggregation.
Finally, Tau alternative splicing is also altered
through genetic mechanisms either direct or indi-
rect. For instance, some mutations have been on
MAPT that lead to mis-splicing of exon 10 and
overexpression of four microtubule-binding
domain Tau isoforms. Tau aggregation can also
show up indirectly, for instance in myotonic dys-
trophy type 1, a neuromuscular disorder. In this
disease, the mRNA of this protein DMBK have CUG
expansion triplets, causing sequestration of splic-
ing factors that can change alternative splicing of
many genes (APP, MAPT, Chloride channel, insulin
receptor, troponin T, etc.). For MAPT, Tau splicing
leads to the formation of the shortest Tau isoform
which is found aggregated in some patients pre-
senting with myotonic dystrophy. In the same way,
some mutations on the Tau gene, MAPT, change
the alternative splicing of Tau. For example, in AD,
the six isoforms of Tau co-aggregate, in contrast to
pathologies like PSP, in which only the 4R-Tau
isoforms aggregate, and Pick’s disease, where the
aggregates are only comprised of 3R-Tau. Adding
additional complexity, autosomal dominant muta-
tions in MAPT have been reported to promote Tau
aggregation and lead to frontotemporal lobar
degeneration.
In AD, there is a large therapeutic time window for
Tau treatments since neurofibrillary tangles last
for decades. This is evident in neurons with
pretangles that are still integrated into neuronal
networks and still functional at early stages of AD
[387]. Preclinical studies are possible because of
the large number of animal models available [388–
390]. Currently, PET ligands, peripheral biomark-
ers, and different therapeutic strategies are avail-
able for Tau therapeutic intervention. In addition,
prevention and environmental factors may have
an effect on Tau pathology and interventions can
be used in combination with other treatments
(Fig. 8).
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There are many hypotheses of Tau aggregation. As
for APP, Tau has chromosome micro-duplications
and deletions important for tauopathies. In addi-
tion, specific haplotypes increase the amount of
Tau, alternative splicing, conformation, posttrans-
lational modification and change in degradation.
All these hypotheses open up new therapeutic
strategies. New therapies implicate for example to
decrease posttranslational modifications like phos-
phorylation. Enhancing Tau dephosphorylation
with sodium selenite is another possibility. Other
approaches are the modulation of Tau
Table 2. Diversity of tauopathies in humans and their main traits
Aetiology Tau lesions Isoforms Refs
Alzheimer’s disease
Down syndrome
Aß, ageing, genetics. . . Neurofibrillary tangles (NFTs)
& dystrophic neurites
3R + 4R [365]
Argyrophilic grain disease Ageing Argyrophilic grains in limbic
areas
4R ≫ 3R [366]
Autism with self-injury
behaviour
Chronic traumatic
encephalopathies
Dementia pugilistica
Traumatic brain injury
Repeated head trauma NFTs & dystrophic neurites
Astrocytic tangles
3R + 4R [367–369]
Postencephalitic
parkinsonism
Subacute sclerosing
panencephalitis
Virus NFTs & dystrophic neurites
Astrocytic tangles
3R + 4R
?
[370, 371]
Progressive supranuclear
palsy
• French Caribbean islands
• Northern France
Amyotrophic lateral scle-
rosis/parkinsonism
dementia syndrome of
Guam
Unknown
Food toxins
Industrial waste
Unknown environment
(food, heavy metals. . .)
NFTs & dystrophic neurites
Tufted astrocytes
4R ≫ 3R
3R + 4R
[372–374]
Corticobasal degeneration Unknown
MAPT haplotypes
NFTs & neurites
Astrocytic plaques
4R ≫ 3R [375, 376]
Pick’s disease Unknown Pick bodies 3R ≫ 4R [375, 377, 378]
Niemann–Pick disease type C Metabolism, genetics NFTs & neurites 3R + 4R [379, 380]
Myotonic dystrophy type 1 Indirect genetics: DMPK
mutations (consequences
on alternative splicing)
NFTs & neurites 0N3R [381, 382]
Frontotemporal lobar
degeneration (FTDP-17)
Direct genetics: MAPT
mutations
NFTs & dystrophic neurites
Astrocytic tangles
Pick bodies. . . (highly
dependent of mutations)
3R + 4R
or
4R ≫ 3R
[383]
Progressive supranuclear
palsy
MAPT haplotypes
miR-132
NFTs & dystrophic neurites
Tufted astrocytes
4R ≫ 3R [384, 385]
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glycosylation, modulation of Tau aggregation
(methylene blue derivatives failed in phase III),
stabilization of microtubules and enhancement
of Tau proteolysis. Immunotherapy is another
very plausible approach. Modulation of alterna-
tive splicing may be an approach through gene
therapy.
Finally, it is important to mention that Tau is not
only a microtubule-associated protein, and its role
in cells is not completely understood. Tau is bound
to the plasma membrane [391], it is involved in
transduction signalling, especially in brain insulin
resistance [281]. It is also present in the nucleus,
where it binds DNA, RNA, and is able to change the
organization of the chromatin [392], thus influenc-
ing gene expression. It is also involved in synaptic
plasticity through interaction with SH3 domains
[394] and mediation of NMDA receptor phosphory-
lation [394].
The links between Ab and Tau are still not fully
defined. This is one of the main problems for
Alzheimer’s disease. For instance, for immunother-
apy against Tau, decreasing its amount will
improve the symptoms in the mouse models but
does not cure the pathology. Thus, the real prob-
lem is that we do not have the right model for AD.
Takomi Saido in Japan developed APP single copy
knock-in mice, which contains the human APP
gene without artefacts related to overexpression
[297]. New Tau knock-in models are currently in
development.
The presence of Amyloid beta and Tau cannot
predict cognitive decline, possibly because of the
Fig. 8 Key targets and therapeutic strategies for Tau treatments. Schematic representation of strategies for preventing Tau
aggregation and spreading. Modulation of Tau metabolism can occur by regulating transcription, phosphorylation and
degradation (e.g. through autophagy in pre- and postsynaptic neurons). Blockade of Tau trans-synaptic transfer through
immunotherapy is also a strategy under test in the clinic.
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cognitive reserve. This point out the fact that we
have too many therapeutic strategies without
knowing the functions of Tau. In order to better
target Tau in AD, research needs to focus on
understanding brain homeostasis, microbial infec-
tions, hormones, about glucose uptake, microglia,
insulin, leptin, ghrelin, and other mechanisms not
really explored in the field yet. Even for
immunotherapy, the mechanisms leading the anti-
bodies to clearing, or to block extracellular amyloid
propagation are not understood, simply because
we do not know how Tau is transferred from one
neuron to another.
Discussion and perspectives
Currently, in the clinic, the diagnosis of AD is
based on symptomatology and, to some extent, on
biomarkers. Memory tests help the neurologist or
geriatrician to first identify dementia and then
screen for Ab via CSF tests, using PET imaging or
both. The symptom-based classification leads to
the staging of AD, as we know it, with MCI in the
early phases and AD with its different stages later
on [395]. Yet, from a neurobiological perspective,
AD leads to synapse loss, neuronal death and
decrease of cognitive function for reasons still
unknown, and progresses in a continuum. There-
fore, it is difficult to divide into defined stages. For
these reasons, the NIA-AA has released a research
framework suggesting a biological definition of AD
based largely on biomarkers from living patients
combined with cognitive tests [310]. These guide-
lines represent an effort to help a more accurate
characterization of the aetiology of AD and help
intervention studies targeting specific pathways
involved in AD. Nevertheless, a clear stratification
of AD requires much more research into the newly
discovered mechanisms of disease progression.
In this work, we have revised the new risk factors
that involve different pathways influencing AD
development. However, screenings for all of these
pathways are challenging for the clinic, sometimes
requiring advanced techniques such as mass spec-
troscopy or special tracers [273]. Many of these
methods require considerable technical knowledge
or are too expensive for basic diagnostic laborato-
ries. Still, the importance of novel biomarker
detection lies in the possibility for intervention
[101, 396, 397], rather than a prediction of AD
progression and thus, represent valuable lines of
research. These new genes and molecules hold the
potential to allow us categorization of AD subtypes
based on the clinical history of the patient [398,
399], improving, in turn, the predictions about the
evolution of the disease and eventually, choosing a
more personalized therapeutic strategy.
Clinical trials for NGF gene delivery in the hip-
pocampus require complex procedures involving
invasive injections in specific nuclei in the brain. It
is possible that small deviations in the injection
site can render the therapy ineffective in terms of
improving cognition in subjects [400], although
NGF cell therapy remains promising and under
clinical research [35]. The unknown origin of the
disease, mixed with complex genetic and environ-
mental factors contributing to pathogenesis, have
challenged clinical trials worldwide [401]. It follows
that investment in AD research from the private
sectors decrease and is virtually inexistent for
promising mechanisms such as vesicular traffick-
ing or autophagy [402].
Still, there are some hopes for drugs tested in
previous trials that have failed in phase II stages.
The FDA grants accelerated approval of drugs that
comply with guidelines classified as a determinant
for a disease. With the aforementioned NIA-AA new
definitions on AD based on biomarkers, these
drugs could still get FDA approval should they
show changes in any of the important biomarkers
in CSF at early stages. Indeed, the preclinical stage
is the go-to stage for testing some of these agents
for improving the predictors of AD progression in
any way [401, 403]. Gene editing and control of
gene expression in the brain are technologies in
very early stages for clinical application [404],
however they are good future approaches in mod-
ifying mechanisms such as synaptic plasticity and
epigenetics, as discussed earlier in this work. We
have revised many approaches directed towards
restoring insulin balance in the brain, or restore
microbiota communities to anti-inflammatory
states. Moreover, combination of the therapeutic
approaches revised here and others remain largely
unexplored and have great potential to alter AD
progression.
The establishment of new biomarkers also corre-
sponds to the discovery of new disease pathways
related to increased risk of developing AD. Now
several studies aim to evaluate the effect of statins
in AD from a mechanistic focus, evaluating new
biomarker molecules such as neprilysin [405, 406].
It is now evident that the field of AD research is
starting to integrate knowledge from diverse
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disciplines. For example, micro RNAs have shown
important roles regulating pathways during AD [47,
48, 407]. Also, recent works have discovered miR
exosomes mediating neuron-astrocyte communica-
tion [408] andnetwork-specific glial functions [409],
whose role in neurodegeneration remains com-
pletely unexplored. New ventures in research from
systems biology and omics approaches aims to
uncover master regulators of disease-specific genes
as novel targets for AD therapeutics [410, 411]. In
this way, these targets will also help to uncover
previously unknown pathways of disease and can
connect previously unrelated cascades underlying
neurodegeneration, similar to what happened
between inflammation, diabetes and obesity [412].
It is worth to mention there is a novel nonpharma-
cological approach aiming to re-establish gamma
oscillations in brains with AD. In order to do so,
40 Hzstimulationpulses areappliedusing soundor
light signals. So far, the therapyhasbeen successful
at restoring memory function in AD mouse models
and a clinical trial is planned with human subjects.
Nevertheless, whether the therapeutic effect is long-
lasting in humans remain to be studied, as well as
the basic mechanisms behind the healing effect
[413].
The direct consequence of these discoveries is that
future therapies are likely to involve multiple
targets and/or multiple strategies to exert an effect
on AD-induced neurodegeneration. Similar strate-
gies have become the norm for other conditions
such as AIDS, cancer or even infectious diseases,
producing health schemes that are virtually equal
to a cure in many cases [414–417]. AD therapeutics
faces great challenges in terms of drug delivery,
toxicity, and maintenance of cognition in patients
[4, 17]. These topics will lead the future of AD basic
research in the long term.
In the short term, the most important strategies to
improve the chances for treating AD are the
targeting of factors increasing the risk of develop-
ing AD. We must underline that many risk factors
for AD are modifiable [418]. In this work, we have
described clinical trials and strategies involving
already approved drugs to alter specific pathways
in the brain at early stages of AD. Some of these
studies have reported improvement in cognition of
patients and have a solid molecular and biochem-
ical background behind them. This evidence call
for larger studies, more thorough stratification of
cohorts, and in-depth research into the mecha-
nisms behind the risk factors involved. Some of
these pathways can tremendously increase the
possibilities for treatment. For example, vascular
dynamics in the brain are susceptible to regulation
from an ‘out of the BBB’ approach [419] and could
consequently improve parallel dysfunctions such
as insulin/glucose availability or amyloid clearing.
As pointed out by leading experts in AD, research-
ers should learn from the previous experiences in
therapeutics and keep developing basic knowledge
about this disease.
Only then, we will crystalize the possibility for
treating AD in our lifetime.
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